Ticagrelor effective at reducing first, as well as recurrent and overall cardiovascular events
Monday, March 26, 2012 - 23:30
in Health & Medicine
New research shows that the use of ticagrelor not only reduces the time to a first cardiovascular event (the metric used in most trials) but also significantly reduces the time to a second cardiovascular event or death, and reduces total events including cardiovascular death, heart attack, stroke, ischemic events and urgent revascularization.